Mark E. Dudley

TL;DR: There was no significant correlation between p53 expression in tumors and recognition by the anti-p53 TCR-transduced T cells, and these studies raise doubts concerning the suitability of targeting p53 in the immunotherapy of cancer patients.

TL;DR: Despite successful clonal repopulation and evidence of in vivo antigen targeting, the poor therapeutic efficacy after the adoptive transfer of autologous MDA-specific T cells raises significant concerns regarding future immunotherapy efforts targeting this class of tumor antigens.

TL;DR: Adoptive cell therapy is the most effective immunotherapy in patients with metastatic melanoma and the recent report of regression of cancer when adoptive cell Therapy was used with peripheral lymphocytes genetically engineered to express antitumor T-cell receptors holds promise for extending the use of adoptive cell therapy to patients with common epithelial cancers.

TL;DR: The methodology described here could be readily applied for engineering CD8+ T cells with antitumor specificity for human adoptive immunotherapy, and afforded optimal lentiviral vector-mediated gene transfer efficiency.

TL;DR: Adoptive transfer of autologous T cells expressing anti-CD19 CARs is an attractive new approach for treating B-cell malignancies after treatment with chemotherapy, and CAR-transduced T cells were widely distributed with the highest levels in the spleen and bone marrow.